SCHEMBL20063247

SCHEMBL20063247

O=C(Nc1cccc(S(=O)(=O)Nc2ccccc2F)c1)c1cccs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 11/20 0.60
▸ KMT2A Q03164 11/20 0.60
▸ MAPT P10636 10/20 0.60
▸ ALDH1A1 P00352 5/20 0.60
▸ APOBEC3G Q9HC16 4/20 0.60
▸ MAPK1 P28482 4/20 0.60
▸ LMNA P02545 8/20 0.58
▸ HPGD P15428 2/20 0.58
▸ PKM P14618 1/20 0.58
▸ MPI P34949 1/20 0.58
▸ POLB P06746 1/20 0.56
▸ NPY1R P25929 1/20 0.56
▸ NPY2R P49146 1/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ KCNK3 O14649 1/20 0.53
▸ KCNK9 Q9NPC2 1/20 0.53
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.51
▸ SLC10A2 Q12908 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30926895 1.00 MEN1 (0.60) MEN1KMT2AMAPTALDH1A1APOBEC3G
SCHEMBL27180073 0.81 KMT2A (0.59) MEN1KMT2AMAPTALDH1A1APOBEC3G
SCHEMBL30926893 0.81 KMT2A (0.59) MEN1KMT2AMAPTALDH1A1APOBEC3G
SCHEMBL833815 0.79 SMN1; SMN2 (0.65) MEN1KMT2AMAPTMAPK1POLB
SCHEMBL30926780 0.78 MAPT (0.65) MEN1KMT2AMAPTALDH1A1APOBEC3G
SCHEMBL30926707 0.78 MAPT (0.76) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL27180759 0.78 MAPT (0.65) MEN1KMT2AMAPTALDH1A1APOBEC3G
SCHEMBL27179632 0.78 MAPT (0.76) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL27925948 0.76 RAB9A (0.64) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL30926551 0.75 MAPT (0.66) MEN1KMT2AMAPTALDH1A1APOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580404-A2 SULFONAMIDE APYRASE INHIBITORS Texas Crop Science, Inc. (US) 2025-07-09 — — EP claimed
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 — — US claimed
WO-2024050041-A2 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE (US) 2024-03-07 — — WO claimed
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 — — US disclosed
WO-2024050041-A2 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE (US) 2024-03-07 — — WO disclosed
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2022-01-18 — — US disclosed
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-04-19 — — US disclosed
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-04-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof PHGDH, PGD, PGK1 MEN1 3225/4885KMT2A 3959/4885MAPT 154/4885
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF PHGDH, PGD, PGK1 MEN1 2720/4885KMT2A 3904/4885MAPT 182/4885
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS APEH, ARSA, DNPEP MEN1 4795/4885KMT2A 2544/4885MAPT 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback